LabCorp to purchase Covance in $6.1B deal

Posted online November 3, 2014 | 6:36 am

LabCorp will pay about $6.1 billion in cash and stock to buy Covance in a tie-up that aims to improve clinical trial research for pharmaceuticals.

Based in Burlington, N.C., LabCorp officials said the new company would improve patient recruitment for trials, make the research more efficient and deliver drug data faster, according to USA TOday.

LabCorp Chairman and CEO David King will lead the combined company.

Read more from USA Today.[[In-content Ad]]

Comments

No comments on this story |

Please log in to add your comment

Buc-ee's sues Marshfield venture Barc-ee's

Editors' Pick

Open for Business: Belamour

Springfield event venue Belamour LLC gained new ownership; The Wok on West Bypass opened; and Hawk Barber & Shop closed on a business purchase that expanded its footprint to Ozark.

Most Read